Skip to main content
Download PDF

Higher levels of circulating desphospho-uncarboxylated matrix Gla protein over time are associated with worse survival: the prospective Maastricht Intensive Care COVID cohort

Journal of Intensive Care volume 11, Article number: 63 (2023) Cite this article

Abstract

Background

Extra-hepatic vitamin K-status, measured by dephosphorylated uncarboxylated matrix Gla protein (dp-ucMGP), maintains vascular health, with high levels reflecting poor vitamin K status. The occurrence of extra-hepatic vitamin K deficiency throughout the disease of COVID-19 and possible associations with pulmonary embolism (PE), and mortality in intensive care unit (ICU) patients has not been studied. The aim of this study was to investigated the association between dp-ucMGP, at endotracheal intubation (ETI) and both ICU and six months mortality. Furthermore, we studied the associations between serially measured dp-ucMGP and both PE and mortality.

Methods

We included 112 ICU patients with confirmed COVID-19. Over the course of 4 weeks after ETI, dp-ucMGP was measured serially. All patients underwent computed tomography pulmonary angiography (CTPA) to rule out PE. Results were adjusted for patient characteristics, disease severity scores, inflammation, renal function, history of coumarin use, and coronary artery calcification (CAC) scores.

Results

Per 100 pmol/L dp-ucMGP, at ETI, the odds ratio (OR) was 1.056 (95% CI: 0.977 to 1.141, p = 0.172) for ICU mortality and 1.059 (95% CI: 0.976 to 1.059, p = 0.170) for six months mortality. After adjustments for age, gender, and APACHE II score, the mean difference in plasma dp-ucMGP over time of ICU admission was 167 pmol/L (95% CI: 4 to 332, p = 0.047). After additional adjustments for c-reactive protein, creatinine, and history of coumarin use, the difference was 199 pmol/L (95% CI: 50 to 346, p = 0.010). After additional adjustment for CAC score the difference was 213 pmol/L (95% CI: 3 to 422, p = 0.051) higher in ICU non-survivors compared to the ICU survivors. The regression slope, indicating changes over time, did not differ. Moreover, dp-ucMGP was not associated with PE.

Conclusion

ICU mortality in COVID-19 patients was associated with higher dp-ucMGP levels over 4 weeks, independent of age, gender, and APACHE II score, and not explained by inflammation, renal function, history of coumarin use, and CAC score. No association with PE was observed. At ETI, higher levels of dp-ucMGP were associated with higher OR for both ICU and six month mortality in crude and adjusted modes, although not statistically significantly.

Introduction

Critical care settings are characterized by an increased risk of malnutrition and micronutrient deficiencies, including vitamin K deficiency [1]. This nutrient is essential for proper coagulation and cardiovascular health [2,3,4]. Emerging evidence suggests that vitamin K deficiency may be particularly relevant in patients with COVID-19 owing to its potential role in immune function and coagulopathy [5,6,7,8,9,10]. In severe COVID-19 cases, immune dysregulation and coagulopathy can lead to microvascular occlusion [11,12,13], multi-organ failure [14], and in turn, increased mortality [15].

Vitamin K is a fat-soluble vitamin that is necessary for the posttranslational gamma-glutamylcarboxylation of certain proteins, including several coagulation factors and matrix Gla protein (MGP) [16]. MGP is a vitamin K-dependent protein that plays a critical role in vascular health. Dephosphorylated uncarboxylated matrix Gla protein (dp-ucMGP) is a circulating biomarker that reflects the levels of inactive MGP and can be used as a marker of extra-hepatic vitamin K status. Higher levels of dp-ucMGP suggest impaired carboxylation of vitamin K-dependent proteins in the vasculature and extra-hepatic vitamin K deficiency [17].

Emerging evidence suggests that extra-hepatic vitamin K deficiency may be associated with worse outcome in COVID-19 [10, 18]. Other studies found that extra-hepatic vitamin K deficiency is associated with more severe lung injury and is potentially linked to thrombotic complications in COVID-19 [6, 9]. Furthermore, it has been associated with more inflammation in these patients [5, 8].

Extra-hepatic vitamin K is essential for proper coagulation and cardiovascular health, and extra-hepatic vitamin K deficiency has been associated with cardiovascular morbidity and development of severe lung injury in COVID-19 patients [6, 9, 10, 18]. Therefore, measuring dp-ucMGP levels over the trajectory of ICU admission in COVID-19 patients may provide insight into the potential association between extra-hepatic vitamin K deficiency and clinical outcomes.

The aim of this study was to investigate whether dp-ucMGP levels during ICU admission are associated with worse clinical outcomes, including thrombotic events and mortality, in critically ill COVID-19 patients. In addition, we investigated whether dp-ucMGP levels reflect cardiovascular morbidity and are associated with the development of severe lung injury.

Methods

The manuscript was written following the STrengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines [19].

Study population

The Maastricht Intensive Care COVID (MaastrICCht) cohort is a prospective cohort of patients with confirmed COVID-19 admitted to the ICU of the Maastricht University Medical Centre (MUMC +). The design has been described extensively elsewhere [20] and includes comprehensive serial hemostasis and coagulation phenotyping [21, 22]. The local institutional review board (Medisch Ethische Toetsingscomissie (METC) 2020-1565/300523) of the MUMC + approved the study, which was performed based on the regulations of Helsinki. The study is registered in International Clinical Trials Registry Platform (NL8613). This study included all participants with respiratory insufficiency requiring mechanical ventilation and at least one real-time polymerase chain reaction (RT-PCR) positive for SARS-CoV-2 RNA and a chest CT scan strongly suggestive of SARS-CoV-2 infection, based on a CORADS-score of 4–5 scored by a radiologist [23, 24]. Participants were followed until they either died in the ICU or were discharged from ICU. A comprehensive and uniform set of clinical, physiological, and laboratory variables was collected daily, reducing the chance of missing data. In addition, when patients were not available for blood sampling or laboratory testing failed, the measurement would be rescheduled for the next blood withdrawal.

Clinical, physiological variables

Variable collection on the ICU for COVID-19 was standardized as described extensively elsewhere [20]. Medical history of cardiovascular disease (defined as congestive heart failure, myocardial infarction, or peripheral vascular disease) was scored on ICU admission. APACHE-II score on ETI and SOFA score during ICU stay were calculated [14]. Coronary artery calcium (CAC) scores were measured within the MaastrICCht cohort, which was described in more detail elsewhere [25]. Patients were classified with or without a clinical PE as follows; in patients with a clinical suspected PE, computed tomography pulmonary angiography (CTPA) was used diagnostically. CTPA was performed in a supine position after intravenous injection of individually adapted contrast media volume (iopromide 300 mg iodine; Ultravist, Bayer Healthcare, Berlin, Germany) based on body weight and kVp settings on a second or third-generation dual source CT scanner (Somatom Definition Flash, Force; Siemens Healthineers, Forchheim Germany). The image quality of all CT scans was judged sufficient to evaluate the presence of PE or thrombosis (central, lobular, segmental, or sub-segmental) [26]. Patients in whom CTPA excluded PE were classified as not having clinical PE. The occurrence of deep venous thrombosis (DVT) diagnosed by ultrasound was recorded within the cohort, but was not considered as the majority of the patients underwent CTPA at ICU admission.

Six months follow-up

Information regarding the six months mortality after endotracheal intubation (ETI) was collected. This was done by identification of the last medical contact consisting of: a consultation in our hospital or hospitalisation, a visit to the emergency room, imaging diagnostics, surgery or the laboratory measurement of a blood sample drawn. When patients had died during the six month follow-up period, this information was collected. Patients who had been transferred to other hospitals, were followed-up by contacting the patients themselves or their general practitioners.

Enteral nutrition

Enteral nutrition in all ICU admitted patients, who were suspected to be unable to ingest oral food within the first 48 h of ICU admission, has been started via naso-gastric tube. Fresubin 1200 (including 10 μg vitamin K /100ml) was the standard nutrition and was prescribed in a weight adjusted dose [27]. The adjusted feeding dose was calculated as follows: day 1; 5ml/kg/day, day 2; 10 ml/kg/day, day 3; 15ml/kg/day, and maximal dosage on day 4; 20ml/kg/day [28].

Anticoagulation

All ICU admitted patients received intermediate doses of thromboprophylaxis: Nadroparin 5700, 7600, and 11,400 IU for respectively < 70, 70–90, and > 90 kg [29]. Patients who required therapeutic anticoagulants before hospital admission were started on therapeutic low molecular weight heparin (LMWH) upon ICU admission. In addition, vitamin K antagonists and direct oral anticoagulants (DOACs) were switched to therapeutic LMWH. Patients on extracorporeal membrane oxygenation (ECMO) or continuous renal replacement therapy (CRRT) received unfractionated heparin (UFH), guided by guidelines based on aPTT (heparin therapeutic range (HTR) 50-80s) and anti-Xa (HTR 0.3 – 0.7 IU/mL) measurements [30].

dp-ucMGP sub-cohort

Two-hundred and thirty-two patients were enrolled in the MaastrICCht cohort from March 25th 2020, until April 13th, 2021. We included patients in the present investigation who had a chest CT scan as part of standard care. The chest CT scan was introduced as standard of care in our hospital during the pandemic to rule out pulmonary embolism, at ICU admission, and was done in each patient. To rule out any selective information bias on coronary calcium, which is important within the pathophysiological framework under investigation, ninety-four patients enrolled early during the COVID-19 pandemic were excluded as they had no standard chest CT scan [31]. Of the total of 232 cohort patients, dp-ucMGP as therefore not measured in the initial 94 patients. Hundred and thirty-eight patients were enrolled in the MaastrICCht cohort, during the second COVID-19 wave, from September 26th, 2020, until April 13th, 2021. Of those hundred thirty eight, a hundred and twelve patients had serial citrate plasma stored to measure dp-ucMGP. No leftover citrate plasma was available in the remaining twenty-six patients, which were excluded (Fig. 1). Timing from ETI allows for a fairer comparison between vitamin K status and the disease course severity, where disease severity is defined as the need for mechanical ventilation in the ICU due to COVID-19. From September 29th onwards, additional dp-ucMGP assays were performed at Monday and Thursday in the morning, in leftover citrate plasma, for all included MaastrICCht cohort patients. Patients who were in the ICU before September 29th or were transported from another hospital after ETI were also included, starting dp-ucMGP measurements from admission from September 29th onwards. This means that the inclusion of patients could vary between the first till the fourth week after ETI. This design has been applied and described more extensively elsewhere [20].

Fig. 1
figure 1

Flowchart patient population. Wave 2 patients had standard CTPA on ICU admission. MaastrICCht Maastricht Intensive Care COVID, dp-ucMGP desphospho-uncarboxylated matrix Gla protein, *dp-ucMGP was measured to determine extra hepatic vitamin K status in a sub-cohort of the Maastricht Intensive Care COVID cohort

Full size image

Blood withdrawal and preparation and laboratory analysis

Daily arterial blood samples from all patients were collected from an arterial line in 7.2 mg K2 EDTA (4.0 mL), serum, or 3.2%(w/v) sodium citrate Vacutainer blood collection tubes (Becton Dickinson, Plymouth, UK). Platelet-poor plasma (PPP) was obtained using two subsequent centrifugation steps: initial centrifugation of 2490g for 5 min, followed by 10,000g for 10 min. Circulating dp-ucMGP levels were determined in citrate plasma using the commercially available IVD chemiluminescent InaKif MGP assay on the IDS-iSYS system (IDS, Boldon, United Kingdom) as previously described [32]. The within-run and total precision of this assay were 0.8–6.2% and 3.0–8.2%, respectively. The assay measuring range is between 200 and 12,000 pmol/L and was found to be linear up to 11,651 pmol/L. dp-ucMGP values < 400 pmol/L are in the normal healthy range and values > 400 pmol/L reflect vitamin K deficiency [17].

Statistical analyses

The data were analyzed with R version 3.6.1. As appropriate, the sample characteristics were described using median and interquartile range (IQR) or percentage. In addition, Pearson’s chi-square test, Mann Witney u test, or Kruskal–Wallis test were performed to compare characteristics. We described the association between serial dp-ucMGP measurements during ICU admission and two outcome variables. First, the cohort participants were categorized based on ICU survivors and ICU non-survivors. Then, we used linear mixed-effects regression with a random intercept and random slope for time to compute average differences in dp-ucMGP over time and differences in the slope over time between both groups. If the slope did not differ, average differences over time are reported only. We computed unadjusted group differences for dp-ucMGP (Model 1). In model 2, we adjusted model 1 for age, gender, and APACHE-II score. In model 3, we additionally adjusted model 2 for C-reactive protein (at ETI), creatinine (at ETI) and history of coumarin use. In addition, to investigate whether differences in dp-ucMGP between ICU survivors and ICU non-survivors were independent of pre-existing cardiovascular disease, we additionally adjusted model 2 for CAC-score (model 4) as more CAC reflects worse cardiovascular disease [31, 32]. Finally, we categorized patients based on the occurrence of PE (CTPA positive vs. CTPA negative) and repeated models 1–3 above. We report regression coefficients β with 95% confidence intervals (95% CI) and considered a p-value < 0.05 statistically significant. In addition, we analysed the associations between dp-ucMGP, per 100 pmol/L, and ICU mortality and six-months mortality, in crude (model 1) and adjusted models (adjusting for age, gender, APACHE II score and c-reactive protein, creatinine, and history of coumarin use (model 2)).

Results

Patient characteristics

Of 112 mechanically ventilated patients, the median [IQR] age was 65 [60–71] years, and 78% were men. Body Mass Index (BMI) was 27.7 [25.4–31.1] (Kg/m2). Before ETI, 27 (24%) participants had cardiovascular disease, 26 (23%) had chronic pulmonary disease, and 5 patients (5%) had a history of coumarin use. CAC scores were measured in 79 (69%) patients. On the moment of ETI, median [IQR] C-reactive protein was 94 [45–154] (mg/L), leukocytes 10.4 [7.2–12.7] (x10E9/L), creatinine 74 [59–97] (µmol/l), alkaline phosphatase 76 [58–108] (IU/L), lactate dehydrogenase was 469 [361–650] (U/L), pt 11.5 [10.9–12.2] (sec), aPTT 30 [27,28,29,30,31,32,33,34,35] (sec), d-dimer 2103 (ng/mL) [1096–7309], thrombocytes 257 (×10E9/L) [177–334] and APACHE II score 15 [13,14,15,16,17,18]. During the ICU stay, 8 patients (7%) underwent renal replacement therapy, and 6 patients (5%) underwent extracorporeal membrane oxygenation (ECMO). The number of ICU survivors was 63 (56%). Age (68 vs. 63 years) and APACHE II score (16 vs. 14) were significantly higher in ICU non-survivors than in ICU survivors, respectively (p < 0.05). BMI (27 vs. 28.7 kg/m2), as well as the leukocytes (9.1 vs. 11.5 × 10E9/L) and thrombocytes (220 vs. 288 × 10E9/L), which were significantly lower in ICU non-survivors (p < 0.05). The number of patients with chronic pulmonary disease (7 vs. 19) was significantly lower in ICU non-survivors as well (p < 0.05). 36 patients (32%) were diagnosed with PE (Table 1). Follow-up was 4 weeks, and the number of analyzed samples per week varied between 25 and 89. The level of dp-ucMGP and SOFA score did not significantly differ between the various time points during follow-up for ICU survivors and ICU non-survivors (Table 2). Figure 2 shows the individual trajectories of measured dp-ucMGP levels (pmol/L) for ICU survivors and ICU non-survivors.

Table 1 Summary of the patient characteristics
Full size table
Table 2 Number of COVID-19 patients, citrate sampling sample dates, desphospho-uncarboxylated matrix Gla protein (dp-ucMGP) levels (pmol/L), routine laboratory measurements, and Sequential Organ Failure Assessment (SOFA) scores per week of intensive care unit (ICU) admission starting from endotracheal intubation for ICU survivors and ICU non-survivors
Full size table
Fig. 2
figure 2

Evolution of desphospho-uncarboxylated matrix Gla protein (dp-ucMGP) levels (pmol/L) for individual patients, during intensive care unit (ICU) stay, for ICU survivors and ICU non-survivors suffering from COVID-19

Full size image

Associations between dp-ucMGP at ETI and both ICU and six months mortality

Per 100 pmol/L dp-ucMGP at ETI the odds ratio for ICU mortality was 1.056 (95% CI: 0.977–1.141) (crude). After adjustment for age, gender, APACHE II score, c-reactive protein (at ETI), creatinine (at ETI), and history of coumarin use, the odds ratio for ICU mortality was 1.072 (95% CI: 0.985–1.166). Per 100 pmol/L dp-ucMGP at ETI the odds ratio for six months mortality was 1.059 (95% CI: 0.976–1.059) (crude). After adjustment for age, gender, APACHE II score, c-reactive protein (at ETI), creatinine (at ETI), and history of coumarin use, the odds ratio for six months mortality was 1.069 (95% CI: 0.984–1.163) (Table 3).

Table 3 Association between desphospho-uncarboxylated matrix Gla protein (dp-ucMGP) levels at the moment of ETI and ICU mortality and six months mortality
Full size table

dp-ucMGP and ICU mortality

The average dp-ucMGP level for ICU survivors was 866 pmol/L (95% CI: 758 to 974) and 1025 pmol/L (95% CI: 906 to 1145) for ICU non-survivors. For ICU non-survivors, the average (95% CI) dp-ucMGP level over time was 159 pmol/L (95% CI: − 2 to 321, p = 0.054) higher compared to the ICU survivors (Table 4, model 1). After adjustment for age, gender, and APACHE II score, the average level of (95% CI) dp-ucMGP over time was 167 pmol/L (95% CI: 4 to 332 p = 0.047) higher for ICU non-survivors compared to the ICU survivors (Table 4, model 2).

Table 4 Linear mixed-effects regression for desphospho-uncarboxylated matrix Gla protein (dp-ucMGP) levels (pmol/L) and intensive care unit (ICU) mortality
Full size table

The role of inflammation, creatinine, history of coumarin use and CAC

Additional adjustments for C-reactive protein, creatinine, and history of coumarin use did not change the difference (Table 4, model 3), which became somewhat greater, (i.e., 213 95% CI (-3 to 422)) after adjustment for CAC scores, between ICU survivors and ICU non-survivors (Table 4, model 4). Differences in average level of dp-ucMGP levels between ICU survivors and ICU non-survivors remain stable over time (p = 0.138) (Fig. 3).

Fig. 3
figure 3

Evolution of desphospho-uncarboxylated matrix Gla protein (dp-ucMGP) levels (pmol/L) during intensive care unit (ICU) stay, for ICU survivors and ICU non-survivors suffering from COVID-19

Full size image

dp-ucMGP and pulmonary embolism in the ICU

The average dp-ucMGP level for patients without PE was 973 pmol/L (95% CI: 875 to 1072), and for patients with PE was 849 pmol/L (95% CI: 700 to 998). For patients with PE, the average (95% CI) dp-ucMGP level over time was -124 pmol/L (95% CI: -301 to 54, p = 0.219) lower compared to patients without PE (Table 5, model 1). Additional adjustments for age, gender, APACHE II score, C-reactive protein at ETI, creatinine at ETI, and history of coumarin use (Table 5, model 3) did not change this result. Differences in average dp-ucMGP did not change over time between patients with or without PE (p = 0.054), (Fig. 4).

Table 5 Linear mixed-effects regression for desphospho-uncarboxylated matrix Gla protein (dp-ucMGP) levels (pmol/L) and pulmonary embolism (PE) in the intensive care unit (ICU)
Full size table
Fig. 4
figure 4

Evolution of desphospho-uncarboxylated matrix Gla protein (dp-ucMGP) levels (pmol/L), during intensive care (ICU) stay, for patients suffering from COVID-19 with approved pulmonary embolism (PE) and patients in which PE was excluded

Full size image

Discussion

This study evaluated the extra-hepatic vitamin K status throughout the disease course of COVID-19 and possible associations with PE, and mortality in ICU admitted patients.

At the moment of ETI, patients with severe COVID-19 had dp-ucMGP levels far above the reference range [17]. This study investigated the association between dp-ucMGP levels and PE in ICU admitted patients. The results showed that dp-ucMGP levels did not differ between patients with PE as compared to those without PE. Therewith, we could not confirm the suggestion that extra-hepatic vitamin K deficiency may play a role in the development of PE in COVID-19 patients [6, 9].

However, dp-ucMGP levels were significantly higher in ICU non-survivors than in survivors, after adjusting for age, gender, and APACHE II score. The average dp-ucMGP level over time was 167 pmol/L higher in ICU non-survivors (p < 0.05). Importantly, the results showed that the observed effect remained unchanged after adjustment for CRP, creatinine, history of coumarin use and also after adjustment for CAC. The latter seems to indicate that dp-ucMGP levels mark cardiovascular disease, which could play a role in ICU mortality in mechanically ventilated COVID-19 patients.

Interestingly, we observed that dp-ucMGP levels were higher at the moment of ETI and did not change over time in both survivors and non-survivors. When we consider only dp-ucMGP levels at ETI, higher levels were associated with higher OR for mortality, for both ICU and six month mortality in crude and adjusted modes, although not statistically significantly. Thus, the serial measurements showing a difference in dp-ucMGP on average over time between survivors and non-survivors, which is present at ETI, although higher dp-ucMGP levels at ETI itself appeared not statistically significantly associated to higher mortality and this is likely due to a type two error (lower power compared to serial dp-ucMGP analyses). These observations are consistent with previous reports of an association between increased inflammation and impaired extra-hepatic vitamin K levels [5, 7, 8]. The fact that dp-ucMGP levels remained lower over time in survivors compared to non-survivors suggests that extrahepatic vitamin K deficiency most likely marks disease severity, while a causal contribution to mortality itself is less likely.

Vitamin K is necessary for the activation of MGP, a protein that plays a key role in vascular calcification and arterial stiffness. Extra-hepatic vitamin K deficiency leads to the accumulation of dp-ucMGP, which has been linked to an increased risk of cardiovascular disease [2, 33,34,35,36]. Our study suggests that vitamin K deficiency, as indicated by elevated dp-ucMGP levels, may be particularly relevant in critically ill COVID-19 patients with pre-existing cardiovascular comorbidities.

Although our results suggest dp-ucMGP as a marker for disease severity previous studies alternatively have suggested that vitamin K itself plays a role in protecting against lung damage [37]. In COVID-19 in particular, some evidence suggests that vitamin K itself may also be relevant potentially acting in immune function and coagulopathy [6, 9]. The latter studies support the concept that vitamin K acts in severe cases of COVID-19 through immune dysregulation and coagulopathy which may lead to microvascular occlusion, multi-organ failure, and increased mortality rates.

The fact that dp-ucMGP levels remained stable over time in the current study does not necessarily contradict the assumption that vitamin K deficiency is associated with lung damage in COVID-19. It is important to note that we did not directly investigate the association between dp-ucMGP levels and COVID-19 or lung damage but rather assessed the levels of dp-ucMGP over time during ICU stay.

Our study had some limitations. First, because of a limited number of blood samples, we did not directly measure vitamin K levels; therefore, we cannot exclude the possibility that other factors may have contributed to the observed associations. Second, our study included only mechanically ventilated COVID-19 patients admitted to the ICU; therefore, our findings may not be generalizable to other patient populations. Finally, we did not investigate the effects of additional vitamin K supplementation on disease outcomes. The causal role vitamin K might play, could possibly be driven by nutrition and cannot be ruled out by our data. However, our manuscript provides more evidence that dp-ucMGP acts as a marker of cardiovascular disease instead of a causal factor. Additional adjustments for CAC did not change our results, however it is unclear if CAC acts as an adequate surrogate measure for cardio-vascular abnormalities in total.

Conclusion

This study provides evidence that extrahepatic vitamin K deficiency, marked by high dp-ucMGP levels, occurs in COVID-19 ICU patients. ICU non-survivors have been shown to have higher dp-ucMGP levels over time, reflecting a more severe extrahepatic vitamin K deficiency which marks more cardiovascular disease. Our results, do neither support nor exclude the concept that vitamin K supplementation favours disease outcomes in COVID-19 patients.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

APACHE:

Acute physiology and chronic health evaluation

aPTT:

Activated partial thromboplastin time

BMI:

Body mass index

CAC:

Coronary artery calcification

COVID:

Coronavirus disease

CRRT:

Continuous renal replacement therapy

CTPA:

Computed tomography pulmonary angiography

DOAC:

Direct oral anticoagulants

dp-ucMGP:

Dephosphorylated uncarboxylated matrix Gla protein

ECMO:

Extracorporeal membrane oxygenation

ETI:

Endotracheal intubation

HTR:

Heparin therapeutic range

ICU:

Intensive care unit

IQR:

Interquartile range

LMWH:

Low molecular weight heparin

MaastrICCht:

Maastricht Intensive care covid

OR:

Odds ratio

PE:

Pulmonary embolism

PT:

Prothombin time

RT-PCR:

Real-time polymerase chain reaction

STROBE:

Strengthening the reporting of observational studies in epidemiology

UFH:

Unfractionated heparin

References

  1. Dahlberg S, Schurgers L, Schott U, Kander T. Vitamin K deficiency in critical ill patients; a prospective observational study. J Crit Care. 2019;49:105–9.

    Article  CAS  PubMed  Google Scholar 

  2. Shioi A, Morioka T, Shoji T, Emoto M. The inhibitory roles of vitamin K in progression of vascular calcification. Nutrients. 2020;12(2):583.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Popa DS, Bigman G, Rusu ME. The role of vitamin K in humans: implication in aging and age-associated diseases. Antioxidants (Basel). 2021;10(4):566.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Suleiman L, Negrier C, Boukerche H. Protein S: a multifunctional anticoagulant vitamin K-dependent protein at the crossroads of coagulation, inflammation, angiogenesis, and cancer. Crit Rev Oncol Hematol. 2013;88(3):637–54.

    Article  PubMed  Google Scholar 

  5. Visser MPJ, Dofferhoff ASM, van den Ouweland JMW, van Daal H, Kramers C, Schurgers LJ, et al. Effects of vitamin D and K on interleukin-6 in COVID-19. Front Nutr. 2021;8: 761191.

    Article  PubMed  Google Scholar 

  6. Dofferhoff ASM, Piscaer I, Schurgers LJ, Visser MPJ, van den Ouweland JMW, de Jong PA, et al. Reduced vitamin K status as a potentially modifiable risk factor of severe coronavirus disease 2019. Clin Infect Dis. 2021;73(11):e4039–46.

    Article  CAS  PubMed  Google Scholar 

  7. Tutusaus A, Mari M, Ortiz-Perez JT, Nicolaes GAF, Morales A, Garcia de Frutos P. Role of vitamin K-dependent factors protein S and GAS6 and TAM receptors in SARS-CoV-2 infection and COVID-19-associated immunothrombosis. Cells. 2020;9(10), 2186

  8. Anastasi E, Ialongo C, Labriola R, Ferraguti G, Lucarelli M, Angeloni A. Vitamin K deficiency and covid-19. Scand J Clin Lab Invest. 2020;80(7):525–7.

    Article  CAS  PubMed  Google Scholar 

  9. Janssen R, Visser MPJ, Dofferhoff ASM, Vermeer C, Janssens W, Walk J. Vitamin K metabolism as the potential missing link between lung damage and thromboembolism in Coronavirus disease 2019. Br J Nutr. 2021;126(2):191–8.

    Article  CAS  PubMed  Google Scholar 

  10. Desai AP, Dirajlal-Fargo S, Durieux JC, Tribout H, Labbato D, McComsey GA. Vitamin K & D deficiencies are independently associated with covid-19 disease severity. Open Forum Infect Dis. 2021;8(10):ofab408.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Alnima T, Mulder MMG, van Bussel BCT, Ten Cate H. COVID-19 coagulopathy: from pathogenesis to treatment. Acta Haematol. 2022;145(3):282–96.

    Article  CAS  PubMed  Google Scholar 

  12. Busch MH, Timmermans S, Nagy M, Visser M, Huckriede J, Aendekerk JP, et al. Neutrophils and contact activation of coagulation as potential drivers of COVID-19. Circulation. 2020;142(18):1787–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Falcinelli E, Petito E, Gresele P. The role of platelets, neutrophils and endothelium in COVID-19 infection. Expert Rev Hematol. 2022;15(8):727–45.

    Article  CAS  PubMed  Google Scholar 

  14. Bels JLM, van Kuijk SMJ, Ghossein-Doha C, Tijssen FH, van Gassel RJJ, Tas J, et al. Decreased serial scores of severe organ failure assessments are associated with survival in mechanically ventilated patients; the prospective Maastricht Intensive Care COVID cohort. J Crit Care. 2021;62:38–45.

    Article  CAS  PubMed  Google Scholar 

  15. Yang W, Kandula S, Huynh M, Greene SK, Van Wye G, Li W, et al. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis. Lancet Infect Dis. 2021;21(2):203–12.

    Article  CAS  PubMed  Google Scholar 

  16. Girolami A, Ferrari S, Cosi E, Santarossa C, Randi ML. Vitamin K-dependent coagulation factors that may be responsible for both bleeding and thrombosis (FII, FVII, and FIX). Clin Appl Thromb Hemost. 2018;24(9 suppl):42S-S47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Cranenburg EC, Koos R, Schurgers LJ, Magdeleyns EJ, Schoonbrood TH, Landewe RB, et al. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost. 2010;104(4):811–22.

    Article  CAS  PubMed  Google Scholar 

  18. Linneberg A, Kampmann FB, Israelsen SB, Andersen LR, Jorgensen HL, Sandholt H, et al. The association of low vitamin K status with mortality in a cohort of 138 hospitalized patients with COVID-19. Nutrients. 2021;13(6):1985.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10): e296.

    Article  Google Scholar 

  20. Tas J, van Gassel RJJ, Heines SJH, Mulder MMG, Heijnen NFL, Acampo-de Jong MJ, et al. Serial measurements in COVID-19-induced acute respiratory disease to unravel heterogeneity of the disease course: design of the Maastricht Intensive Care COVID cohort (MaastrICCht). BMJ Open. 2020;10(9): e040175.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Hulshof AM, Bruggemann RAG, Mulder MMG, van de Berg TW, Sels JEM, Olie RH, et al. Serial EXTEM, FIBTEM, and tPA Rotational Thromboelastometry Observations in the Maastricht Intensive Care COVID Cohort-Persistence of Hypercoagulability and Hypofibrinolysis Despite Anticoagulation. Front Cardiovasc Med. 2021;8: 654174.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. van den Berg TW, Mulder MMG, Alnima T, Nagy M, van Oerle R, Beckers EAM, et al. Serial thrombin generation and exploration of alternative anticoagulants in critically ill COVID-19 patients: Observations from Maastricht Intensive Care COVID Cohort. Front Cardiovasc Med. 2022. https://0-doi-org.brum.beds.ac.uk/10.3389/fcvm.2022.929284.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Prokop M, van Everdingen W, van Rees Vellinga T, Quarles van Ufford H, Stoger L, Beenen L, et al. CO-RADS: a categorical CT assessment scheme for patients suspected of having COVID-19-definition and evaluation. Radiology. 2020;296(2):E97-E104.

  24. Schalekamp S, Bleeker-Rovers CP, Beenen LFM, Quarles van Ufford HME, Gietema HA, Stoger JL, et al. Chest CT in the emergency department for diagnosis of COVID-19 pneumonia: Dutch experience. Radiology. 2021;298(2):E98-E106.

  25. Martens B, Driessen RGH, Brandts L, Hoitinga P, van Veen F, Driessen M, et al. Coronary artery calcifications are associated with more severe multiorgan failure in patients with severe coronavirus disease 2019 infection: longitudinal results of the Maastricht intensive care COVID cohort. J Thorac Imaging. 2022;37(4):217–24.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033–69, 69a-69k.

  27. Complete F. https://www.fresubin.be/nl-be/producten/fresubin-1200-complete/.

  28. Singer P, Blaser AR, Berger MM, Alhazzani W, Calder PC, Casaer MP, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr. 2019;38(1):48–79.

    Article  PubMed  Google Scholar 

  29. coagulopathie FmsLC-. 2020. https://www.demedischspecialist.nl/nieuws/leidraad-covid-19-coagulopathie. Accessed 16 Apr 2020.

  30. Streng AS, Delnoij TSR, Mulder MMG, Sels J, Wetzels RJH, Verhezen PWM, et al. Monitoring of unfractionated heparin in severe COVID-19: an observational study of patients on CRRT and ECMO. TH Open. 2020;4(4):e365–75.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Muller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995–2002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Jaminon AMG, Dai L, Qureshi AR, Evenepoel P, Ripsweden J, Soderberg M, et al. Matrix Gla protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease. Sci Rep. 2020;10(1):6586.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Jespersen T, Mollehave LT, Thuesen BH, Skaaby T, Rossing P, Toft U, et al. Uncarboxylated matrix Gla-protein: a biomarker of vitamin K status and cardiovascular risk. Clin Biochem. 2020;83:49–56.

    Article  CAS  PubMed  Google Scholar 

  34. Hou YC, Lu CL, Zheng CM, Chen RM, Lin YF, Liu WC, et al. Emerging role of vitamins D and K in modulating uremic vascular calcification: the aspect of passive calcification. Nutrients. 2019;11(1):152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Spronk HM, Soute BA, Schurgers LJ, Cleutjens JP, Thijssen HH, De Mey JG, Vermeer C. Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun. 2001;289(2):485–90.

    Article  CAS  PubMed  Google Scholar 

  36. Schurgers LJ, Uitto J, Reutelingsperger CP. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol Med. 2013;19(4):217–26.

    Article  CAS  PubMed  Google Scholar 

  37. Drent M, Wijnen P, Bast A. Pharmacogenetic variants and vitamin K deficiency: a risk factor or trigger for fibrosing interstitial pneumonias? Curr Opin Pulm Med. 2018;24(3):287–95.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the ILD care foundation for financially supporting the dp-ucMGP measurements.

Funding

In the current study, the laboratory measurements were funded by the ILD care foundation.

Author information

Author notes

  1. Marjolein Drent and Bas C. T. van Bussel share last authorship.

Authors and Affiliations

  1. Department of Intensive Care Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands

    Mark M. G. Mulder, Joep Schellens, Jan-Willem E. M. Sels, Frank van Rosmalen, Ruud Segers, Walther N. K. A. van Mook, Iwan C. C. van der Horst & Bas C. T. van Bussel

  2. Department of Anaesthesiology, Maastricht University Medical Centre+, Maastricht, The Netherlands

    Mark M. G. Mulder

  3. Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The Netherlands

    Jan-Willem E. M. Sels

  4. Central Diagnostic Laboratory, Maastricht University Medical Centre+, Maastricht, The Netherlands

    Anne-Marije Hulshof, Femke de Vries & Yvonne M. C. Henskens

  5. Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands

    Henri M. H. Spronk, Hugo ten Cate & Leon J. Schurgers

  6. Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands

    Casper Mihl

  7. Academy for Postgraduate Medical Training, Maastricht University Medical Centre+, Maastricht, The Netherlands

    Walther N. K. A. van Mook

  8. School of Health Professions Education, Maastricht University, Maastricht, The Netherlands

    Walther N. K. A. van Mook

  9. Department of Pharmacology and Toxicology, Maastricht University, Maastricht, The Netherlands

    Aalt Bast & Marjolein Drent

  10. Thrombosis Expert Centre Maastricht and Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands

    Henri M. H. Spronk & Hugo ten Cate

  11. Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands

    Mark M. G. Mulder, Jan-Willem E. M. Sels, Anne-Marije Hulshof, Femke de Vries, Casper Mihl, Henri M. H. Spronk, Yvonne M. C. Henskens, Iwan C. C. van der Horst, Hugo ten Cate, Leon J. Schurgers & Bas C. T. van Bussel

  12. ILD Centre of Excellence, Department of Respiratory Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands

    Marjolein Drent

  13. ILD Care Foundation Research Team, Ede, The Netherlands

    Marjolein Drent

  14. Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands

    Bas C. T. van Bussel

Authors
  1. Mark M. G. Mulder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joep Schellens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan-Willem E. M. Sels
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Frank van Rosmalen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anne-Marije Hulshof
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Femke de Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ruud Segers
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Casper Mihl
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Walther N. K. A. van Mook
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Aalt Bast
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Henri M. H. Spronk
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yvonne M. C. Henskens
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Iwan C. C. van der Horst
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hugo ten Cate
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Leon J. Schurgers
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Marjolein Drent
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Bas C. T. van Bussel
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MM was a contributor in writing the study protocol and the manuscript, JS was a contributor in writing in writing the manuscript, JWS was a contributor in writing the study protocol and critical feedback to the manuscript, FR contribution to the data analysis, AMH critical feedback to the manuscript, FV contribution to the laboratory analysis, RS was a contributor in writing the study protocol, CM critical feedback to the manuscript, WM was a contributor in writing the study protocol and critical feedback to the manuscript, AB was a contributor in writing the study protocol, HS critical feedback to the manuscript, YH critical feedback to the manuscript, IH was a contributor in writing the study protocol and the manuscript, HC contribution to the study protocol and critical feedback to the manuscript, LS contribution to the study protocol and critical feedback to the manuscript, MD contribution to the study protocol and critical feedback to the manuscript, BB contribution to the study protocol and contribution in writing the manuscript.

Corresponding author

Correspondence to Mark M. G. Mulder.

Ethics declarations

Ethics approval and consent to participate

Ethical approval has been obtained from the medical ethics committee (Medisch Ethische Toetsingscommissie 2020-1565/3 00 523) of the Maastricht University Medical Centre + (Maastricht UMC +), which will be performed based on the Declaration of Helsinki. During the pandemic, the board of directors of Maastricht UMC + adopted a policy to inform patients and ask their consent to use the collected data and to store serum samples for COVID-19 research purposes. All study documentation will be stored securely for fifteen years after recruitment of the last patient. The results will be published in peer-reviewed academic journals, with a preference for open access journals, while particularly considering deposition of the manuscripts on a preprint server early. We should inform the reader that the Dutch trial register, in which the cohort had been registered initially, has later been passed over to the international clinical trial registry program. However, our original trial register number remains the same (NL8613).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mulder, M.M.G., Schellens, J., Sels, JW.E.M. et al. Higher levels of circulating desphospho-uncarboxylated matrix Gla protein over time are associated with worse survival: the prospective Maastricht Intensive Care COVID cohort. j intensive care 11, 63 (2023). https://0-doi-org.brum.beds.ac.uk/10.1186/s40560-023-00712-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s40560-023-00712-0

Keywords

Journal of Intensive Care

ISSN: 2052-0492